| Top 5 Stories : |
|
A Blueprint for Launch
As new drug launches proliferate in the hotly contested specialty therapeutic space, companies are finding that success is often pre-determined by actions that take place very early in the development and commercialization cycle.
Read more
|
|
|
|
|
Are Global Markets Free-riding on the United States?
The global free-riding problem is the perception that the U.S. is subsidizing drugs for the rest of the world due to high drug prices in the United States compared to other countries in the world, but this is a complicated case to make, and the issue goes far beyond just getting a free ride.
Read more
|
|
|
|
|
Adapt or Die: Nine Pharma Lessons from the Battlefield
The pharmaceutical industry is essential to the innovation that leads to new cures and treatments for patients worldwide. It is important to our nation that the pharmaceutical industry continues to thrive. I am convinced that a key element of this is effective, adaptive leadership.
Read more
|
|
|
| Trending on Social Media : |
Biosimilars: Finding the Right Path to Differentiation
Biosimilars are coming. How will biosimilar value-added marketing measure up to the innovator behemoths? Value needs to extend far beyond modest price reduction and will be measured by a unique set of expectations coming to the US.
Read more
|
We Need New Financial Models for Biomedical Innovation
The ongoing battle over drug reimbursement and pricing has raised questions about whether the pharmaceutical industry can continue to rely on high U.S. revenues to fund biopharmaceutical R&D.
Read more
|
Memes: How is Pharma Using Them?
Because of perpetual regulatory uncertainty about how to do so in the modern/social media sphere, pharma's voice is awfully quiet outside of traditional venues like print, TV, in doctors' offices and at professional events.
Read more
|
|
|
| Follow Us |
|
|
|
|
